The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
AD Nygaard, PC Holdgaard, KL Spindler… - British journal of …, 2014 - nature.com
Background: Cell-free DNA (cfDNA) circulating in the blood holds a possible prognostic
value in malignant diseases. Under malignant conditions, the level of cfDNA increases but …
value in malignant diseases. Under malignant conditions, the level of cfDNA increases but …
Lung cancer genotype-based therapy and predictive biomarkers: present and future
PT Cagle, TC Allen - Archives of pathology & laboratory …, 2012 - meridian.allenpress.com
Context.—The advent of genotype-based therapy and predictive biomarkers for lung cancer
has thrust the pathologist into the front lines of precision medicine for this deadly disease …
has thrust the pathologist into the front lines of precision medicine for this deadly disease …
Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
M Faehling, J Achenbach, P Staib, U Steffen… - Journal of Cancer …, 2018 - Springer
Purpose The controlled phase III trial SATURN demonstrated that maintenance therapy with
erlotinib after the first-line platinum-based chemotherapy prolonged progression-free …
erlotinib after the first-line platinum-based chemotherapy prolonged progression-free …
[HTML][HTML] Better to be alone than in bad company: the antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
N Van Der Steen, C Deben… - World journal of …, 2016 - ncbi.nlm.nih.gov
AIM To investigate the potential benefit of combining the cMET inhibitor crizotinib and
cisplatin we performed in vitro combination studies. METHODS We tested three different …
cisplatin we performed in vitro combination studies. METHODS We tested three different …
[PDF][PDF] 表皮生长因子受体在靶向治疗非小细胞肺癌中的研究进展
权修权， 金明姬， 尹学哲， 高钟镐 - 中国医药生物技术, 2014 - cmbp.net.cn
肺癌是最常见的恶性肿瘤之一, 其发病率和死亡率呈逐年上升趋势, 在全世界癌症死亡中占第一
位[1]. 按照临床和组织病理学特征, 肺癌分为非小细胞肺癌(non-small cell lung cancers …
位[1]. 按照临床和组织病理学特征, 肺癌分为非小细胞肺癌(non-small cell lung cancers …
[PDF][PDF] Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?
M Zippi, A De Quarto, C Marzano, C Cassieri… - Italian Journal of …, 2017 - italjmed.org
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related dead worldwide
and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with …
and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with …
[PDF][PDF] Ο ρόλος των βιολογικών παραγόντων στην αντιμετώπιση ασθενών με μη μικροκυτταρικό καρκίνο του πνεύμονα
Ε Μπούτσικου - 2014 - ikee.lib.auth.gr
Σήμερα ο τρόπος που αντιμετωπίζουμε το καρκίνο του πνεύμονα έχει αλλάξει προς μία πιο
ορθολογιστική χρήση των θεραπευτικών μας επιλογών. Από το μοντέλο του 20ου αιώνα που …
ορθολογιστική χρήση των θεραπευτικών μας επιλογών. Από το μοντέλο του 20ου αιώνα που …
Lungenkarzinom und Pleuramesotheliom
D Ukena - Der Pneumologe, 2013 - Springer
Das Lungenkarzinom ist die dritthäufigste Krebserkrankung in Deutschland und ist die
häufigste zum Tode führende Krebserkrankung. In den zurückliegenden Jahren wurden …
häufigste zum Tode führende Krebserkrankung. In den zurückliegenden Jahren wurden …